The efficacy, safety and tolerability of nabiximols (Sativex) as an adjunctive treatment to existing anti-spasticity medications in children aged 8 to 18 years with spasticity due to cerebral palsy who have not responded adequately to their existing anti-spasticity medications: a parallel group randomised, double-blind, placebo-controlled study.

Trial Profile

The efficacy, safety and tolerability of nabiximols (Sativex) as an adjunctive treatment to existing anti-spasticity medications in children aged 8 to 18 years with spasticity due to cerebral palsy who have not responded adequately to their existing anti-spasticity medications: a parallel group randomised, double-blind, placebo-controlled study.

Completed
Phase of Trial: Phase III

Latest Information Update: 23 May 2017

At a glance

  • Drugs Nabiximols (Primary)
  • Indications Cerebral palsy
  • Focus Registrational; Therapeutic Use
  • Sponsors GW Pharmaceuticals
  • Most Recent Events

    • 16 May 2017 Status changed from active, no longer recruiting to completed.
    • 10 May 2017 This trial has been completed in Czech Republic (end date: 23 Mar 2017).
    • 09 Aug 2016 Planned End Date changed from 1 Dec 2016 to 1 Apr 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top